Go Pro
→ A “bloodbath” Is Coming (From TradeSmith) (Ad)tc pixel
NASDAQ:BMRA

Biomerica Q2 2025 Earnings Report

Biomerica logo
$2.51 +0.15 (+6.36%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$2.50 -0.01 (-0.40%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Biomerica EPS Results

Actual EPS
-$0.48
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Biomerica Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biomerica Announcement Details

Quarter
Q2 2025
Date
1/14/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Biomerica's next earnings date is estimated for Wednesday, October 21, 2026, based on past reporting schedules.

Conference Call Resources

Biomerica Earnings Headlines

Biomerica Posts Narrower Q4 Loss On Higher Sales; Stock Down
September 2, 2026  |  rttnews.comhttps://www.rttnews.com/3687774/biomerica-posts-narrower-q4-loss-on-higher-sales-stock-down.aspx
Biomerica Reports Fiscal 2026 Fourth-Quarter Sales Growth, Improved Full-Year Loss and Advances in inFoods IBS Commercialization
September 1, 2026  |  quiverquant.comQ
A new kind of civil war is coming after election day?
Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the political and investment landscape. Whitney Tilson believes tensions may come to a head at midnight on November 4th, the day after the midterm elections, with major implications for your portfolio.tc pixel
September 20 at 1:00 AM  |  Stansberry Research (Ad)
Biomerica Reports Fiscal 2026 Year-End Financial Results
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354133/0/en/biomerica-reports-fiscal-2026-year-end-financial-results.html
Biomerica Inc.
August 31, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/bmra-biomerica-inc/vitals
Biomerica Announces $2.23 Million Private Placement at $1.60 per Share and Engages B. Riley to Review Strategic Alternatives
August 27, 2026  |  quiverquant.comQ
See More Biomerica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biomerica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biomerica and other key companies, straight to your email.

About Biomerica

Biomerica (NASDAQ:BMRA) is a medical technology company that develops, manufactures and commercializes diagnostic and therapeutic products, with a primary focus on gastrointestinal disorders and other medical conditions. The company is headquartered in Irvine, California, and serves healthcare providers and patients in the United States and selected international markets through direct sales and distribution relationships.

Biomerica’s principal product is inFoods IBS, a diagnostic-guided dietary management program for irritable bowel syndrome. The program combines a blood-based test intended to identify foods that may contribute to an individual’s symptoms with a personalized dietary plan designed to help patients manage those symptoms. Biomerica has also developed and marketed diagnostic products addressing gastrointestinal and infectious-disease applications.

The company has historically focused on combining diagnostic testing with individualized treatment or dietary-management approaches. Zackary Irani serves as Biomerica’s president and chief executive officer and has been associated with the company’s leadership for several years.

View Biomerica Profile
Earnings Tools